2[1]Faloon BJ,Heagerty AM.In vitro perfusion study of human resistance artery function in essential hypertension.J Hypertens,1994,24:14
3[2]Ohtawa M,Takayama F,Saiton K.Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan,an orally active nonpeptide angiotension Ⅱ receptor antagonist,in human.Br J Clin Pharmacol,1993,25:290
4[3]Hegner G,Faust G,Freytag F,et al.A new antagonist for the treatment of essential hypertension:efficacy and safety compared to hydrochlorothiazide.Eur J Pharmacol,1997,52:173
5[4]Klaus D.The role of calcium antagonists in the treatment of hypertension.J Cardiovas Pharmacol,1998,20(suppl 6):s5
6[1]Fassbinder W,Quarder O,Waltz A.Treatment with carvedilol is associated with a significant reduction in microalbuminuria:a multicentre randomized study[J].Int J Clin Pract,1999,53(7):519-522.
7[2]Agrawal B,Abraham WT,Tsvetkova T,et al.Carvedilol improves renal hemodynamics in patients with chronic heart failure[J].J Cardiac Failure,1998,4(Suppl.1):Abstract 5 .
8[3]Yue T-L,Mckenna PJ,Lysko PG,et al.Carvedilol,a new antihypertensive,prevents oxidation of human low density lipoprotein by macrophages and copper[J].Atherosclerosis ,1992,97:209-216.
9[4]Agrawal B,Wolf K,Berger A.Effect of various antihypertensive treatments on the progress of microalbuminuria in non-diabetic hypertensives.Vienna:European Dialysis and Transplant Association,1994.Abstract
10[5]McTavish D,Campoli-Richards D,Sorkin EM.Carvedilol:A review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy[J].Drugs,1993,45(2):232-258.
